The prospective adalimumab biosimilar CinnoRA was shown in a recently published phase 3 trial to be comparable to AbbVie’s innovator biological treatment Humira in terms of safety and efficacy in adult patients with active rheumatoid arthritis.
The prospective adalimumab biosimilar CinnoRA (under development by CinnaGen Co, based in Alborz, Iran) was shown in a recently published phase 3 trial to be comparable to AbbVie’s innovator biological treatment Humira in terms of safety and efficacy in adult patients with active rheumatoid arthritis (RA). The study, by Ahmadreza Jamshidi, MD, professor of internal medicine, Rheumatology Research Center at Tehran University of Medical Sciences, Tehran, Iran, and colleagues, was published online in Arthritis Research & Therapy and registered with the Iranian Registry of Clinical Trials.
This randomized, double-blind, active-controlled, noninferiority trial recruited 136 adult patients with active RA to receive 40 mg subcutaneous injections of either CinnoRA or Humira every other week while receiving methotrexate (15 mg/week), folic acid (1 mg/day), and prednisolone (7.5 mg/day) over a 24-week period. Physical examinations—including vital sign evaluations and laboratory testing—were conducted at baseline, 12 weeks, and 24 weeks. The 68 patients randomized to each arm of the study had comparable demographic information, lab results, and disease characteristics at baseline; 64 patients in each group completed the 24-week study period.
The study’s primary endpoint was the proportion of patients achieving a moderate or good disease activity score of 28 (based on the European League Against Rheumatism [EULAR] response rate) in terms of joints-erythrocyte sedimentation rate (DAS28-ESR). Secondary endpoints were the proportion of patients achieving American College of Rheumatology (ACR) criteria for 20% (ACR20), 50% (ACR50), and 70% (ACR70) responses (measured as improvement in tender and swollen joint counts; patient assessments of pain, global disease activity, and physical function; physician global assessment of disease activity; and acute phase reactant), a disability index of health assessment questionnaire (HAQ), and safety.
The proportion of patients achieving good and moderate EULAR responses in the CinnoRA group was noninferior to the Humira group at 12 and 24 weeks, based on both intention-to-treat and per-protocol populations (all P values >.05). There were no significant differences in the proportion of patients achieving ACR20, ACR50, and ACR70 responses in the CinnoRA and Humira groups (all P values >.05).
The difference in HAQ scores and safety outcome measures between treatment arms was not statistically significant, the researchers noted. Four patients withdrew from the CinnoRA group due to adverse drug reactions (ADRs; n = 2), a positive tuberculin test (n = 1), and poor compliance (n = 1). Similarly, 4 patients left the Humira group because of ADRs (n = 3) and poor compliance (n = 1). The researchers did not notice any significant difference in the incidence of injection site reactions as the most prevalent adverse events between treatment arms.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.